ERBB2 and breast carcinoma: Compared to naïve exosomes, HER2- and EGFR-targeting exosomes demonstrated enhanced delivery to HER2- or EGFR-expressing breast cancer cells in vitro, with approximately 2-fold and ~2–3-fold higher accumulation, respectively [93,94].